● WEEKEND | NEXT OPEN: 2026-09-14 09:30 ET | 07:22 ET | PRICES DELAYED 15 MIN | NYSE · NASDAQ · TSX

TRIB/Trinovium cooling analysis

BULLISH by u/Valuable-Lemon-8623 | Jun 29, 2026 | 1↑ 0 comments | 26 views | VIEW ON REDDIT
$TRIB
$TRIB TRINITY BIOTECH PLC HEALTHCARE EQUITY SIMULATION
$0.41
+0.05 (+13.81%)
LAST PRICE · 15 MIN DELAY
DAY CHG +13.81%
5D CHG -29.36%
30D CHG -32.84%
AI SUMMARY — Trinovium (TRIB) is positioned as a micro-cap turnaround play with existing manufacturing capacity for AI data center cooling fluids, targeting 45-55% gross margins on direct-to-chip solutions plus 75-85% margins on software monitoring platforms. Key catalysts include removal of toxic Yorkville equity line, creditor support restructuring convertible debt, strong Q1 2026 results (43% revenue growth, margin expansion), and potential hyperscaler contracts before August 18 Nasdaq deadline, though execution risk remains high as a speculative micro-cap.
TICKERTRIB USERu/Valuable-Lemon-8623
RATING BULLISH ENTRY $0.44
POSITION 24408 sh SYN BOOK VAL $10739.52
CURRENT $0.41 P&L % -6.89%
CURR VAL $9999.96 P&L $ -739.56

Too lazy to write the DD myself so I let AI write it. NFA regards

Instant Infrastructure Asset: Leverages existing US/EU manufacturing facilities with empty capacity capable of pumping out millions of liters of high-purity fluid annually—zero capital expenditures needed to start mixing AI coolants.
The High-Margin Hybrid Business: The data center direct-to-chip chemical layer targets standard 45% to 55% gross margins, while their planned software-enabled real-time fluid health platform promises high-margin (75% to 85%) recurring revenue.
Toxic Overhang Removed Today: Officially canceled their Yorkville Advisors equity line today (June 29, 2026), immediately stopping the automated, discounted retail share-dumping that historically killed upward momentum.
Lender Restructuring Support: Main creditor (Perceptive Advisors) is supporting the operational turnaround by capitalizing interest payments and aggressively slashing convertible debt conversion floors down to $0.5061 per share to clear the debt load into equity.
Core Business Turnaround Already Exists: Q1 2026 earnings proved the turnaround is working independently of AI—revenue surged 43% to $10.8M, gross margins expanded from 25.2% to 35.4%, and they just bagged an order for over 2 million additional rapid HIV tests.
Micro-Cap Explosion Potential: Trading as a deep-value micro-cap, the market float is exceptionally tight. The stock is tightly wound to violently re-rate on the chart the exact second they announce their first formal hyperscaler or supply-chain validation contract before the August 18, 2026 Nasdaq compliance deadline.